Rice Hall James & Associates LLC boosted its position in shares of Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) by 23.4% during the second quarter, Holdings Channel reports. The firm owned 244,795 shares of the company’s stock after buying an additional 46,482 shares during the period. Rice Hall James & Associates LLC’s holdings in Aerie Pharmaceuticals were worth $12,864,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. BlackRock Inc. increased its position in shares of Aerie Pharmaceuticals by 113,376.8% in the first quarter. BlackRock Inc. now owns 2,600,888 shares of the company’s stock worth $117,951,000 after buying an additional 2,598,596 shares during the period. Russell Investments Group Ltd. increased its position in shares of Aerie Pharmaceuticals by 813.5% in the second quarter. Russell Investments Group Ltd. now owns 232,610 shares of the company’s stock worth $12,223,000 after buying an additional 207,146 shares during the period. FMR LLC increased its position in shares of Aerie Pharmaceuticals by 178.7% in the first quarter. FMR LLC now owns 320,500 shares of the company’s stock worth $14,535,000 after buying an additional 205,500 shares during the period. Suffolk Capital Management LLC increased its position in shares of Aerie Pharmaceuticals by 753.3% in the second quarter. Suffolk Capital Management LLC now owns 145,853 shares of the company’s stock worth $7,665,000 after buying an additional 128,760 shares during the period. Finally, Vanguard Group Inc. increased its position in shares of Aerie Pharmaceuticals by 7.1% in the first quarter. Vanguard Group Inc. now owns 1,392,525 shares of the company’s stock worth $63,151,000 after buying an additional 92,463 shares during the period. 92.98% of the stock is owned by institutional investors.

Shares of Aerie Pharmaceuticals, Inc. (AERI) opened at 50.35 on Friday. The firm has a 50-day moving average of $54.55 and a 200 day moving average of $48.00. The firm’s market cap is $1.83 billion. Aerie Pharmaceuticals, Inc. has a 52 week low of $18.35 and a 52 week high of $59.50.

Aerie Pharmaceuticals (NASDAQ:AERI) last posted its quarterly earnings results on Tuesday, August 1st. The company reported ($0.82) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.84) by $0.02. Equities research analysts predict that Aerie Pharmaceuticals, Inc. will post ($2.56) EPS for the current fiscal year.

TRADEMARK VIOLATION NOTICE: This report was reported by Watch List News and is owned by of Watch List News. If you are viewing this report on another site, it was copied illegally and republished in violation of United States and international copyright legislation. The legal version of this report can be viewed at https://www.watchlistnews.com/rice-hall-james-associates-llc-has-12-86-million-position-in-aerie-pharmaceuticals-inc-aeri/1478100.html.

A number of analysts have recently issued reports on AERI shares. Zacks Investment Research cut shares of Aerie Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Tuesday, July 11th. HC Wainwright restated a “buy” rating and set a $69.00 target price on shares of Aerie Pharmaceuticals in a research note on Thursday, May 25th. BidaskClub cut shares of Aerie Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research note on Saturday, June 17th. Canaccord Genuity restated a “buy” rating and set a $56.00 target price on shares of Aerie Pharmaceuticals in a research note on Tuesday, April 18th. Finally, Stifel Nicolaus restated a “buy” rating on shares of Aerie Pharmaceuticals in a research note on Friday, May 26th. One research analyst has rated the stock with a sell rating, two have given a hold rating, eleven have assigned a buy rating and one has issued a strong buy rating to the stock. The company presently has an average rating of “Buy” and an average price target of $66.08.

In other Aerie Pharmaceuticals news, major shareholder Foresite Capital Fund Ii, L.P. sold 20,000 shares of the company’s stock in a transaction dated Friday, May 26th. The shares were sold at an average price of $55.95, for a total transaction of $1,119,000.00. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. 9.36% of the stock is owned by corporate insiders.

Aerie Pharmaceuticals Company Profile

Aerie Pharmaceuticals, Inc is a clinical-stage pharmaceutical company. The Company is engaged in the discovery, development and commercialization of therapies for the treatment of patients with glaucoma and other diseases of the eye. The Company’s product candidates include Rhopressa (netarsudil ophthalmic solution) 0.02% (Rhopressa), and Roclatan (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005% (Roclatan).

Want to see what other hedge funds are holding AERI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Aerie Pharmaceuticals, Inc. (NASDAQ:AERI).

Institutional Ownership by Quarter for Aerie Pharmaceuticals (NASDAQ:AERI)

Receive News & Ratings for Aerie Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aerie Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.